Education
About Us
Working with TipRanks
Follow Us
NeoGenomics (NEO)
NASDAQ:NEO
NEO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.05 - $19.12
Previous CloseN/A
Volume108.49K
Average Volume (3M)1.68M
Market Cap
$1.28B
Enterprise Value$2.31B
Total Cash (Recent Filing)$1.66M
Total Debt (Recent Filing)$5.91M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Apr 29, 2025EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding128,656,900
10 Day Avg. Volume1,583,353
30 Day Avg. Volume1,678,308
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit7.98
Enterprise Value/Ebitda-1.53K
Forecast
1Y Price Target
$16.78Price Target Upside68.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
---
NeoGenomics News
PremiumCompany Announcements
NeoGenomics Reports Strong Q1 2025 Performance
PremiumCompany Announcements
NeoGenomics Reports Strong Q1 2025 Earnings Growth---
Bulls Say, Bears Say
Bulls Say
Acquisition StrategyThe acquisition of Pathline LLC provides NeoGenomics with a strengthened commercial presence in the Northeast, faster turnaround times, and incremental volume for its higher-margin molecular testing.
Product DevelopmentNeoGenomics is pursuing a strategy of launching several smaller, line extension products each year, expected to contribute to long-term sales growth.
ValuationShares offer compelling long-term upside with current valuation underappreciating growth and profitability potential.
Bears Say
CEO ChangeShares are off 46% following a surprise CEO change and a slight miss to first-quarter revenue consensus.
Financial PerformanceThe company expects a net loss of ($85)-($76) million for the full year 2025, partly due to increased stock compensation and other expenses.
Revenue ImpactGross margins for the Pathline acquisition are below NeoGenomics Inc.'s average, and revenues per test are expected to temporarily decrease.
---
Ownership Overview
1.04% Insiders
35.30% Mutual Funds
0.13% Other Institutional Investors
38.14% Public Companies and
Individual Investors
NEO FAQ
What was NeoGenomics’s price range in the past 12 months?
NeoGenomics lowest stock price was $8.05 and its highest was $19.11 in the past 12 months.
What is NeoGenomics’s market cap?
NeoGenomics’s market cap is $1.28B.
When is NeoGenomics’s upcoming earnings report date?
NeoGenomics’s upcoming earnings report date is Apr 29, 2025 which is yesterday.
How were NeoGenomics’s earnings last quarter?
NeoGenomics released its earnings results on Apr 29, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.013 by $0.013.
Is NeoGenomics overvalued?
According to Wall Street analysts NeoGenomics’s price is currently Undervalued.
Does NeoGenomics pay dividends?
NeoGenomics does not currently pay dividends.
What is NeoGenomics’s EPS estimate?
NeoGenomics’s EPS estimate is -0.01.
How many shares outstanding does NeoGenomics have?
NeoGenomics has 128,656,900 shares outstanding.
What happened to NeoGenomics’s price movement after its last earnings report?
NeoGenomics reported an EPS of $0 in its last earnings report, beating expectations of -$0.013. Following the earnings report the stock price went down -14.008%.
Which hedge fund is a major shareholder of NeoGenomics?
Currently, no hedge funds are holding shares in NEO
---
NeoGenomics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.78 (68.30% Upside)
$16.78 (68.30% Upside)
Blogger Sentiment
Neutral
NEO Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 345.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 7.8%
Last 30 Days ▼ 7.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.49%
12-Months-Change
Fundamentals
Return on Equity
-8.54%
Trailing 12-Months
Asset Growth
-2.57%
Trailing 12-Months
Company Description
NeoGenomics
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
---
NEO Company Deck
---
NEO Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment overall, with significant growth in revenue and EBITDA, expansion through acquisitions, and strong performance in clinical testing volumes and NGS revenue. However, there were challenges in the non-clinical sector, particularly in pharma and biotech spending. Despite these challenges, the company's strategic initiatives and market positioning in oncology provide a robust outlook.Read More>---
NEO Stock 12 Month Forecast
Average Price Target
$16.78
▲(68.30% Upside)
Technical Analysis
---